28 related articles for article (PubMed ID: 17453292)
1. Major histocompatibility complex class I molecule expression by pancreatic cancer cells is regulated by activation and inhibition of the epidermal growth factor receptor.
Knoche SM; Larson AC; Brumfield GL; Cate S; Hildebrand WH; Solheim JC
Immunol Res; 2022 Jun; 70(3):371-391. PubMed ID: 35303241
[TBL] [Abstract][Full Text] [Related]
2. Loss of copy numbers of retrotransposons (HERVK) on chromosome 7p11.2 impacts EGFR (Epidermal Growth Factor Receptor)-induced phenotypes for platinum sensitivity and long-term survival in ovarian cancer-A study from the OVCAD consortium.
Fromhage G; Obermayr E; Bednarz-Knoll N; Van Gorp T; Welsch E; Polterauer S; Braicu EI; Mahner S; Sehouli J; Vergote I; Concin N; Kurtz S; Steinbiss S; Torge A; Zeillinger R; Wölber L; Brandt B
Int J Cancer; 2024 May; ():. PubMed ID: 38709956
[TBL] [Abstract][Full Text] [Related]
3. Basic principles and technologies for deciphering the genetic map of cancer.
Voidonikolas G; Kreml SS; Chen C; Fisher WE; Brunicardi FC; Gibbs RA; Gingras MC
World J Surg; 2009 Apr; 33(4):615-29. PubMed ID: 19115029
[TBL] [Abstract][Full Text] [Related]
4. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors.
Amador ML; Oppenheimer D; Perea S; Maitra A; Cusatis G; Iacobuzio-Donahue C; Baker SD; Ashfaq R; Takimoto C; Forastiere A; Hidalgo M
Cancer Res; 2004 Dec; 64(24):9139-43. PubMed ID: 15604284
[TBL] [Abstract][Full Text] [Related]
5. CYP1A1*2A polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA)n polymorphism.
Nie Q; Yang XN; An SJ; Zhang XC; Yang JJ; Zhong WZ; Liao RQ; Chen ZH; Su J; Xie Z; Wu YL
Eur J Cancer; 2011 Sep; 47(13):1962-70. PubMed ID: 21616658
[TBL] [Abstract][Full Text] [Related]
6. Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer.
Han SW; Jeon YK; Lee KH; Keam B; Hwang PG; Oh DY; Lee SH; Kim DW; Im SA; Chung DH; Heo DS; Bang YJ; Kim TY
Pharmacogenet Genomics; 2007 May; 17(5):313-9. PubMed ID: 17429313
[TBL] [Abstract][Full Text] [Related]
7. EGFR genomic gain and aberrant pathway signaling in pancreatic cancer patients.
Tzeng CW; Frolov A; Frolova N; Jhala NC; Howard JH; Vickers SM; Buchsbaum DJ; Heslin MJ; Arnoletti JP
J Surg Res; 2007 Nov; 143(1):20-6. PubMed ID: 17950068
[TBL] [Abstract][Full Text] [Related]
8. Exon 19 of EGFR mutation in relation to the CA-repeat polymorphism in intron 1.
Sueoka-Aragane N; Imai K; Komiya K; Sato A; Tomimasu R; Hisatomi T; Sakuragi T; Mitsuoka M; Hayashi S; Nakachi K; Sueoka E
Cancer Sci; 2008 Jun; 99(6):1180-7. PubMed ID: 18422739
[TBL] [Abstract][Full Text] [Related]
9. Pancreatic cancer epidermal growth factor receptor (EGFR) intron 1 polymorphism influences postoperative patient survival and in vitro erlotinib response.
Tzeng CW; Frolov A; Frolova N; Jhala NC; Howard JH; Vickers SM; Buchsbaum DJ; Heslin MJ; Arnoletti JP
Ann Surg Oncol; 2007 Jul; 14(7):2150-8. PubMed ID: 17453292
[TBL] [Abstract][Full Text] [Related]
10. Erlotinib: success of a molecularly targeted agent for the treatment of advanced pancreatic cancer.
Welch SA; Moore MJ
Future Oncol; 2007 Jun; 3(3):247-54. PubMed ID: 17547518
[TBL] [Abstract][Full Text] [Related]
11. Erlotinib-induced skin rash. Pathogenesis, clinical significance and management in pancreatic cancer patients.
Saif MW; Merikas I; Tsimboukis S; Syrigos K
JOP; 2008 May; 9(3):267-74. PubMed ID: 18469438
[TBL] [Abstract][Full Text] [Related]
12. Lessons from Tarceva in pancreatic cancer: where are we now, and how should future trials be designed in pancreatic cancer?
Laurent-Puig P; Taieb J
Curr Opin Oncol; 2008 Jul; 20(4):454-8. PubMed ID: 18525343
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
